We are analyzing https://link.springer.com/article/10.1186/1471-2407-14-518.

Title:
Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver | BMC Cancer
Description:
Background Colorectal cancer is the third most frequently diagnosed cancer and the third cause of cancer deaths in the United States. Despite the fact that tumor cell-intrinsic mechanisms controlling colorectal carcinogenesis have been identified, novel prognostic and diagnostic tools as well as novel therapeutic strategies are still needed to monitor and target colon cancer progression. We and others have previously shown, using mouse models, that the extracellular matrix (ECM), a major component of the tumor microenvironment, is an important contributor to tumor progression. In order to identify candidate biomarkers, we sought to define ECM signatures of metastatic colorectal cancers and their metastases to the liver. Methods We have used enrichment of extracellular matrix (ECM) from human patient samples and proteomics to define the ECM composition of primary colon carcinomas and their metastases to liver in comparison with normal colon and liver samples. Results We show that robust signatures of ECM proteins characteristic of each tissue, normal and malignant, can be defined using relatively small samples from small numbers of patients. Comparisons with gene expression data from larger cohorts of patients confirm the association of subsets of the proteins identified by proteomic analysis with tumor progression and metastasis. Conclusions The ECM protein signatures of metastatic primary colon carcinomas and metastases to liver defined in this study, offer promise for development of diagnostic and prognostic signatures of metastatic potential of colon tumors. The ECM proteins defined here represent candidate serological or tissue biomarkers and potential targets for imaging of occult metastases and residual or recurrent tumors and conceivably for therapies. Furthermore, the methods described here can be applied to other tumor types and can be used to investigate other questions such as the role of ECM in resistance to therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

ecm, colon, proteins, cancer, samples, tumor, liver, normal, tumors, primary, figure, article, colorectal, metastasis, pubmed, metastases, enrichment, patients, google, scholar, metastatic, data, gene, tissue, additional, file, cas, matrix, signatures, matrisome, detected, protein, extracellular, genes, identified, patient, set, expression, tissues, analysis, progression, proteomics, composition, study, clinical, biomarkers, methods, sets, authors, institute,

Topics {✒️}

proteomics-derived gene set lc-ms/ms runs open access license pre-publication history developing proteomics-based biomarkers tumor-specific spliced isoform article download pdf author information authors proteomics-derived ecm signatures integrative cancer research clinical expression datasets gene expression data explore potential correlations alexandra naba article naba metastatic colorectal cancer metastatic colorectal cancers rabbit anti-actin antibody tumor-derived ecm proteins identified patient-specific sets related subjects lc-ms/ms primary colon carcinoma final ecm-enriched samples extracellular matrix constituents national cancer institute intra-patient reproducibility assessed privacy choices/manage cookies extracellular matrix signatures metastatic colon cancer gene expression experiments metastatic colon cancers metastasis microarray samples nat rev cancer primary colorectal carcinomas aggressive colorectal cancer primary colorectal tumor matched normal samples primary colon cancers extracellular matrix proteins mgh tissue bank cellular tumor microenvironment clinical data sets tumor extracellular matrices bmc cancer 14 colon cancer enrichment unique gene symbols massachusetts general hospital primary colon carcinomas colorectal tumor progression

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver
         description:Colorectal cancer is the third most frequently diagnosed cancer and the third cause of cancer deaths in the United States. Despite the fact that tumor cell-intrinsic mechanisms controlling colorectal carcinogenesis have been identified, novel prognostic and diagnostic tools as well as novel therapeutic strategies are still needed to monitor and target colon cancer progression. We and others have previously shown, using mouse models, that the extracellular matrix (ECM), a major component of the tumor microenvironment, is an important contributor to tumor progression. In order to identify candidate biomarkers, we sought to define ECM signatures of metastatic colorectal cancers and their metastases to the liver. We have used enrichment of extracellular matrix (ECM) from human patient samples and proteomics to define the ECM composition of primary colon carcinomas and their metastases to liver in comparison with normal colon and liver samples. We show that robust signatures of ECM proteins characteristic of each tissue, normal and malignant, can be defined using relatively small samples from small numbers of patients. Comparisons with gene expression data from larger cohorts of patients confirm the association of subsets of the proteins identified by proteomic analysis with tumor progression and metastasis. The ECM protein signatures of metastatic primary colon carcinomas and metastases to liver defined in this study, offer promise for development of diagnostic and prognostic signatures of metastatic potential of colon tumors. The ECM proteins defined here represent candidate serological or tissue biomarkers and potential targets for imaging of occult metastases and residual or recurrent tumors and conceivably for therapies. Furthermore, the methods described here can be applied to other tumor types and can be used to investigate other questions such as the role of ECM in resistance to therapy.
         datePublished:2014-07-18T00:00:00Z
         dateModified:2014-07-18T00:00:00Z
         pageStart:1
         pageEnd:12
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/1471-2407-14-518
         keywords:
            Extracellular matrix
            Proteomics
            Colorectal cancer
            Metastasis
            Tumor microenvironment
            Matrisome
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig4_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alexandra Naba
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
                     name:Massachusetts Institute of Technology
                     address:
                        name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Karl R Clauser
               affiliation:
                     name:Broad Institute of MIT and Harvard
                     address:
                        name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Charles A Whittaker
               affiliation:
                     name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center
                     address:
                        name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steven A Carr
               affiliation:
                     name:Broad Institute of MIT and Harvard
                     address:
                        name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kenneth K Tanabe
               affiliation:
                     name:Massachusetts General Hospital Cancer Center
                     address:
                        name:Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard O Hynes
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
                     name:Massachusetts Institute of Technology
                     address:
                        name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver
      description:Colorectal cancer is the third most frequently diagnosed cancer and the third cause of cancer deaths in the United States. Despite the fact that tumor cell-intrinsic mechanisms controlling colorectal carcinogenesis have been identified, novel prognostic and diagnostic tools as well as novel therapeutic strategies are still needed to monitor and target colon cancer progression. We and others have previously shown, using mouse models, that the extracellular matrix (ECM), a major component of the tumor microenvironment, is an important contributor to tumor progression. In order to identify candidate biomarkers, we sought to define ECM signatures of metastatic colorectal cancers and their metastases to the liver. We have used enrichment of extracellular matrix (ECM) from human patient samples and proteomics to define the ECM composition of primary colon carcinomas and their metastases to liver in comparison with normal colon and liver samples. We show that robust signatures of ECM proteins characteristic of each tissue, normal and malignant, can be defined using relatively small samples from small numbers of patients. Comparisons with gene expression data from larger cohorts of patients confirm the association of subsets of the proteins identified by proteomic analysis with tumor progression and metastasis. The ECM protein signatures of metastatic primary colon carcinomas and metastases to liver defined in this study, offer promise for development of diagnostic and prognostic signatures of metastatic potential of colon tumors. The ECM proteins defined here represent candidate serological or tissue biomarkers and potential targets for imaging of occult metastases and residual or recurrent tumors and conceivably for therapies. Furthermore, the methods described here can be applied to other tumor types and can be used to investigate other questions such as the role of ECM in resistance to therapy.
      datePublished:2014-07-18T00:00:00Z
      dateModified:2014-07-18T00:00:00Z
      pageStart:1
      pageEnd:12
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/1471-2407-14-518
      keywords:
         Extracellular matrix
         Proteomics
         Colorectal cancer
         Metastasis
         Tumor microenvironment
         Matrisome
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-518/MediaObjects/12885_2014_Article_4731_Fig4_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alexandra Naba
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
                  name:Massachusetts Institute of Technology
                  address:
                     name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Karl R Clauser
            affiliation:
                  name:Broad Institute of MIT and Harvard
                  address:
                     name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Charles A Whittaker
            affiliation:
                  name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center
                  address:
                     name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steven A Carr
            affiliation:
                  name:Broad Institute of MIT and Harvard
                  address:
                     name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kenneth K Tanabe
            affiliation:
                  name:Massachusetts General Hospital Cancer Center
                  address:
                     name:Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard O Hynes
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
                  name:Massachusetts Institute of Technology
                  address:
                     name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Massachusetts Institute of Technology
      address:
         name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:Broad Institute of MIT and Harvard
      address:
         name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
         type:PostalAddress
      name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center
      address:
         name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, Cambridge, USA
         type:PostalAddress
      name:Broad Institute of MIT and Harvard
      address:
         name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
         type:PostalAddress
      name:Massachusetts General Hospital Cancer Center
      address:
         name:Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alexandra Naba
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
            name:Massachusetts Institute of Technology
            address:
               name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Karl R Clauser
      affiliation:
            name:Broad Institute of MIT and Harvard
            address:
               name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Charles A Whittaker
      affiliation:
            name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center
            address:
               name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Steven A Carr
      affiliation:
            name:Broad Institute of MIT and Harvard
            address:
               name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Kenneth K Tanabe
      affiliation:
            name:Massachusetts General Hospital Cancer Center
            address:
               name:Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
               type:PostalAddress
            type:Organization
      name:Richard O Hynes
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
            name:Massachusetts Institute of Technology
            address:
               name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
      name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA
      name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
      name:David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, Cambridge, USA
      name:Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, USA
      name:Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
      name:David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
      name:Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, USA

External Links {🔗}(151)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.36s.

LINK . SPRINGER . COM {}